Comparison of adjuvant treatment regimens for high-risk hepatocellular carcinoma: a Bayesian network meta analysis and systematic review

被引:0
作者
Li, Jiahao [1 ]
Liu, Yingnan [2 ]
Qiu, Yuqi [1 ]
Qu, Chao [1 ]
Li, Jiarui [1 ]
机构
[1] First Hosp Jilin Univ, Dept Intervent Therapy, Changchun, Jilin, Peoples R China
[2] First Hosp Jilin Univ, Dept Radiol, Changchun, Jilin, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
hepatocellular carcinoma; TACE; HAIC; adjuvant therapy; immunotherapy; network meta-analysis; OPEN-LABEL; BEVACIZUMAB; SORAFENIB; PLUS;
D O I
10.3389/fimmu.2024.1487353
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The five-year recurrence rate for patients with hepatocellular carcinoma (HCC) is as high as 70%. Patients with high-risk recurrence factors experience significantly poorer prognosis. Local regional therapies, including transarterial chemoembolisation (TACE), hepatic arterial infusion chemotherapy (HAIC), radiotherapy, and emerging immunotherapy, are commonly used adjuvant treatment options. We conducted an indirect comparison of these adjuvant therapies for such patients. Methods: We conducted a systematic search in public databases for relevant studies and assessed the efficacy and safety of the corresponding therapies by consolidating disease-free survival (DFS), overall survival (OS), and adverse events (AEs). Results: A total of eight randomised controlled trials were ultimately included. The Gelman-Rubin plot and kernel density estimation indicate that the stability of the combined model is satisfactory. Conclusion: immunotherapy is not inferior to local regional therapies in delaying tumour recurrence, however, the higher incidence of AEs remains a significant concern. Adjuvant radiotherapy demonstrated superior efficacy in delaying tumour recurrence compared to adjuvant TACE, although further support from phase III clinical trial evidence is required. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024576316.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Wang, Yani
    Lau, Wanyee
    Li, Yafei
    Tian, Yichen
    Lei, Yongrong
    Wang, Jianhua
    Xia, Feng
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (11) : 3590 - 3601
  • [22] Treatment of hepatocellular carcinoma with macroscopic vascular invasion: A systematic review and network meta-analysis
    Tustumi, Francisco
    Coelho, Fabricio Ferreira
    Magalhaes, Daniel de Paiva
    Silveira Junior, Sergio
    Jeismann, Vagner Birk
    Fonseca, Gilton Marques
    Kruger, Jaime Arthur Pirola
    D'Albuquerque, Luiz Augusto Carneiro
    Herman, Paulo
    TRANSPLANTATION REVIEWS, 2023, 37 (03)
  • [23] Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion
    Li, Ming-Feng
    Leung, Henry W. C.
    Chan, Agnes L. F.
    Wang, Shyh-Yau
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1157 - 1168
  • [24] Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
    Antonio Giovanni Solimando
    Nicola Susca
    Antonella Argentiero
    Oronzo Brunetti
    Patrizia Leone
    Valli De Re
    Rossella Fasano
    Markus Krebs
    Elisabetta Petracci
    Irene Azzali
    Oriana Nanni
    Nicola Silvestris
    Angelo Vacca
    Vito Racanelli
    Clinical and Experimental Medicine, 2022, 22 : 65 - 74
  • [25] A Network Meta-analysis of the Efficacy of Drug Therapy in First-line Treatment of Advanced Hepatocellular Carcinoma
    Wang, Xinchou
    Peng, Gaoyao
    Li, Jiangfa
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2024, 33 (01) : 94 - 101
  • [26] Cost effectiveness of immune checkpoint inhibitors for treatment of Hepatocellular Carcinoma: A systematic review and Meta-analysis
    Dawood, Zaiba Shafik
    Brown, Zachary J.
    Endo, Yutaka
    Katayama, Erryk S.
    Munir, Muhammad Musaab
    Alaimo, Laura
    Ruff, Samantha M.
    Lima, Henrique A.
    Woldesenbet, Selamawit
    Pawlik, Timothy M.
    SURGICAL ONCOLOGY-OXFORD, 2023, 51
  • [27] Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis
    Ba, He
    Zhu, Fangyuan
    Zhang, Xiaoze
    Mei, Zubing
    Zhu, Yaodong
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [28] Demographics and Immunotherapy Efficacy for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Phase III Clinical Trials
    Shao, Yu-Yun
    Akhmetzhanov, Andrei R.
    LIVER CANCER, 2024,
  • [29] Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis
    Feng, Fan
    Jiang, Qiyu
    Jia, Hui
    Sun, Huiwei
    Chai, Yantao
    Li, Xiaojuan
    Rong, Guanghua
    Zhang, Yingshi
    Li, Zhengping
    PHARMACOLOGICAL RESEARCH, 2018, 135 : 89 - 101
  • [30] What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis
    Xie, Hui
    Yu, Haipeng
    Tian, Shengtao
    Yang, Xueling
    Wang, Ximing
    Yang, Zhao
    Wang, Huaming
    Guo, Zhi
    ONCOTARGET, 2017, 8 (59) : 100508 - 100523